Merck & Co Inc (MRK)

MRK on New York Consolidated

55.51USD
22 Oct 2014
Price Change (% chg)

$0.38 (+0.69%)
Prev Close
$55.13
Open
$55.23
Day's High
$55.86
Day's Low
$55.00
Volume
12,903,038
Avg. Vol
9,554,252
52-wk High
$61.33
52-wk Low
$44.62

MRK

Chart for MRK

About

Merck & Co., Inc. (Merck), is a global health care company that delivers health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products, which it markets directly and through its joint ventures. The Company consists of four operating segments, which are the Pharmaceut... (more)

Overall

Beta: 0.43
Market Cap (Mil.): $159,029.80
Shares Outstanding (Mil.): 2,884.63
Dividend: 0.44
Yield (%): 3.19

Financials

  MRK Industry Sector
P/E (TTM): 29.06 32.90 33.54
EPS (TTM): 1.90 -- --
ROI: 6.92 18.34 17.61
ROE: 11.71 19.01 18.42
Search Stocks

Roche, Merck extend immunotherapy fight to breast cancer

LONDON - Swiss drugmaker Roche and U.S. group Merck & Co are to present data on their rival immunotherapy drugs in breast cancer in December, extending the novel approach to fighting tumors to another cancer type.

17 Oct 2014

Roche, Merck extend immunotherapy fight to breast cancer

LONDON - Swiss drugmaker Roche and U.S. group Merck & Co are to present data on their rival immunotherapy drugs in breast cancer in December, extending the novel approach to fighting tumours to another cancer type.

17 Oct 2014

UPDATE 1-Roche, Merck extend immunotherapy fight to breast cancer

(Adds Merck also presenting breast cancer data in December)

17 Oct 2014

Merck unit to pay $31 million to settle fraud claims by U.S. states

- A subsidiary of Merck & Co has agreed to pay U.S. states $31 million to settle claims that it overcharged their Medicaid programs for an antidepressant it had sold at a discount to pharmacy companies, attorney generals from three states said on Wednesday.

15 Oct 2014

Merck unit to pay $31 mln to settle fraud claims by U.S. states

Oct 15, - A subsidiary of Merck & Co has agreed to pay U.S. states $31 million to settle claims that it overcharged their Medicaid programs for an antidepressant it had sold at a discount to pharmacy companies, attorney generals from three states said on Wednesday.

15 Oct 2014

Geographic split likely for GSK mature drugs sale: sources

LONDON - GlaxoSmithKline is seeking binding bids by next month for a range of older drugs worth more than $3 billion, which it is likely to sell by geographical region, according to people with direct knowledge of the process.

14 Oct 2014

Geographic split likely for GSK mature drugs sale -sources

LONDON, Oct 14 - GlaxoSmithKline is seeking binding bids by next month for a range of older drugs worth more than $3 billion, which it is likely to sell by geographical region, according to people with direct knowledge of the process.

14 Oct 2014

Fitch Rates Merck's EUR Debt Offering 'A+'; Outlook Negative

(The following statement was released by the rating agency) CHICAGO, October 06 (Fitch) Fitch Ratings has assigned an 'A+' rating Merck & Co.'s (Merck) Euro denominated senior unsecured notes offering. Merck intends to use all or a substantial portion of the net proceeds from the offering to refinance existing debt. The Rating Outlook is Negative and applies to approximately $23.1 billion in outstanding debt. A full list of Merck's ratings follows near the end of this release. KEY RATING DR

06 Oct 2014

New Issue- Merck & Co prices multi tranche deal

Lead Manager(s) JP Morgan, Deutsche Bank AG, BNP Paribas, BAML, RBS, BBVA,

06 Oct 2014

UPDATE 1-Esperion drug succeeds in lowering LDL cholesterol -study

Oct 1 - An experimental cholesterol-fighting drug being developed by Esperion Therapeutics Inc lowered LDL levels significantly more than Merck & Co Inc's Zetia in a midstage clinical trial, Esperion said on Wednesday.

01 Oct 2014

Competitors

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider: Stock Traders Daily
$20.00
Provider: Thomson Reuters Stock Report
$25.00
Provider: New Constructs, LLC
$25.00
Provider: MacroRisk Analytics/EconomicInvestor
$25.00
Provider: ValuEngine, Inc.
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Search Stocks